Repatha Cost in North Carolina 2026: Price, Insurance, Medicaid, and Compounded Evolocumab

What Is the Cash Price of Repatha in North Carolina in 2026?

The Amgen wholesale acquisition cost for Repatha sits at approximately $580 per month in 2026, whether you pick it up at a Walgreens in Charlotte or an independent pharmacy in Asheville. That figure has remained largely flat since Amgen introduced modest list-price reductions in 2019 in response to payer pressure. Without insurance or a manufacturer coupon, $580 is effectively what most North Carolina retail pharmacies charge at the point of sale.

For context, the FOURIER trial (N=27,564) demonstrated that evolocumab 140 mg every two weeks reduced LDL-C by 59% from baseline and cut the composite of cardiovascular death, MI, and stroke by 15% over a median of 26 months in patients with established atherosclerotic cardiovascular disease [1]. That degree of LDL lowering is not achievable with any generic statin alone for high-risk patients who are statin-intolerant or have familial hypercholesterolemia, which is precisely why payers still face pressure to cover the drug despite its cost.

The FDA granted evolocumab its initial approval on August 27, 2015, for adults with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), and established cardiovascular disease requiring additional LDL-C lowering [2]. The label specifies 140 mg subcutaneously every two weeks or 420 mg once monthly, delivered via the SureClick autoinjector or the Pushtronex monthly device [2].

GoodRx and similar discount aggregators occasionally list prices between $540 and $575 at NC pharmacies after their negotiated discounts, but these figures shift weekly. The safest current price check is always the pharmacy's direct cash-pay quote combined with the Amgen savings program described below [3].

How North Carolina Medicaid Covers Repatha (or Does Not)

North Carolina Medicaid's coverage of Repatha is narrow. As of 2026, the NC Medicaid preferred drug list covers evolocumab only for the type 2 diabetes indication, specifically as adjunctive therapy in adults with type 2 diabetes and established cardiovascular disease [4]. Patients seeking coverage for heterozygous or homozygous familial hypercholesterolemia or for general ASCVD risk reduction without a diabetes diagnosis will find the drug is not covered under standard NC Medicaid without a successful non-preferred exception appeal.

This restriction is significant because the ACC/AHA 2018 guideline on blood cholesterol management explicitly states: "In patients with very high-risk ASCVD, use of a PCSK9 inhibitor is recommended if LDL-C remains ≥70 mg/dL on maximally tolerated statin plus ezetimibe therapy" [5]. North Carolina Medicaid's narrower formulary position diverges from that recommendation for non-diabetic ASCVD patients.

To pursue a prior authorization exception for FH or ASCVD without diabetes, prescribers typically need to document: maximum tolerated statin dose with inadequate LDL-C response, LDL-C above 100 mg/dL (or above 70 mg/dL for very high-risk patients), and documented cardiovascular events or FH diagnosis confirmed by genetic testing or clinical criteria. The NC DHHS Medicaid Clinical Coverage Policy 8C outlines the appeals framework, and most exceptions must be submitted through NCTracks [4].

Medicaid managed care plans operating in NC (Carolina Complete Health, Healthy Blue, UnitedHealthcare Community Plan, WellCare, and Ambetter) each apply their own prior authorization criteria on top of the state PDL, so criteria vary slightly by plan. Calling the specific plan's pharmacy help desk before submitting a PA is worth the 15 minutes it takes.

Commercial Insurance and Prior Authorization in North Carolina

Most commercial insurers operating in North Carolina, including Blue Cross and Blue Shield of NC, Aetna, Cigna, and UnitedHealthcare, place Repatha on a specialty tier requiring prior authorization and often step therapy [6]. Step therapy typically mandates a documented trial of at least two statins at maximally tolerated doses, frequently with the addition of ezetimibe, before evolocumab will be approved.

Blue Cross NC's 2026 specialty formulary, for example, classifies evolocumab as a Tier 4 specialty drug with a 30-day supply cost-share that can reach $150 to $300 per fill for patients who have not met their deductible, even after the PA is granted [6]. Patients on high-deductible health plans may face the full WAC until their deductible is satisfied, at which point the tier-4 copay kicks in.

The American College of Cardiology's 2022 expert consensus decision pathway noted that "PCSK9 inhibitor therapy is cost-effective at a threshold of $50,000 to $150,000 per quality-adjusted life year when used in very high-risk patients," a range that many private payers now reference when setting utilization management criteria [7]. That analysis supports coverage but does not compel it, which is why PA denials remain common even for clearly indicated patients.

If a commercial PA is denied, North Carolina's 2023 prior authorization reform law (Session Law 2023-58) requires insurers to issue initial decisions on standard PA requests within 5 business days and urgent requests within 72 hours, and to provide written reasons for any denial [8]. Patients can use that written denial to file an external appeal through the NC Department of Insurance.

The Amgen Repatha Savings Card: How It Works in North Carolina

Amgen's copay assistance program for commercially insured patients in North Carolina offers a monthly cost as low as $0, capped at savings of up to $3,600 per year per patient [3]. Patients sign up at Amgen's patient support site and present the savings card (or its digital equivalent) at the pharmacy alongside their commercial insurance card. The card covers the gap between what insurance pays and the patient's copay or coinsurance, up to the annual cap.

The program excludes patients whose primary coverage is a federal or state government program, meaning Medicare Part D, Medicaid, and Tricare enrollees are ineligible [3]. Patients who hit the $3,600 annual cap, typically those on high-deductible plans with large early-year out-of-pocket exposure, may see their monthly cost rise to $200 to $300 for the remainder of the benefit year.

For uninsured patients, Amgen operates a separate patient assistance program, Repatha Assist, which may provide the drug at no cost for patients below certain income thresholds. In 2025, the income cutoff was approximately 600% of the federal poverty level [3]. Applications go through Amgen's enrollment form and require proof of income and a prescriber signature.

Compounded Evolocumab in North Carolina: Legality and Cost

Compounded evolocumab is legally available in North Carolina through pharmacies operating under Section 503A of the Federal Food, Drug, and Cosmetic Act, provided specific conditions are met [9]. A 503A pharmacy compounds for individual patients in response to a valid prescriber order and is licensed by the NC Board of Pharmacy. The compounded product is not FDA-approved, meaning it has not undergone the same efficacy and safety review as brand Repatha, but the active molecule, evolocumab, is the same biologic sequence when properly compounded [9].

The FDA's guidance on compounding of biologics notes that PCSK9 inhibitors fall into a legally complex category because evolocumab is a monoclonal antibody. Compounding a biologic from raw materials requires a pharmacy with protein-handling capabilities and validated sterile technique [10]. Not every 503A pharmacy in North Carolina has that capacity. Patients should verify that the compounding pharmacy holds current NC Board of Pharmacy licensure, uses a Certificate of Analysis from a USP-compliant API supplier, and follows USP chapter 797 sterile compounding standards [10].

When a licensed 503A pharmacy does supply compounded evolocumab, the cost is often dramatically lower than brand Repatha's $580 list price, with some pharmacies charging in the range of $100 to $200 per month. HealthRX telehealth providers can connect North Carolina patients with vetted 503A compounding pharmacies that meet all federal and state requirements.

Three practical decision points for patients considering compounded evolocumab in NC:

1. Confirm the pharmacy's 503A status with the NC Board of Pharmacy online license lookup before filling any prescription.
2. Ask for the compounded product's certificate of analysis showing potency, sterility, and endotoxin testing.
3. Discuss with your prescriber whether the compounded formulation can be used at the same FDA-approved 140 mg or 420 mg dose equivalents.

Insurance does not cover compounded evolocumab, so this route is primarily relevant for uninsured patients or those who cannot access the Amgen savings card.

Telehealth Prescribing of Repatha in North Carolina

North Carolina permits telehealth prescribing of Repatha under the state's telehealth statute (N.C. Gen. Stat. § 90-18.2), which allows licensed NC physicians and advanced practice providers to prescribe via synchronous audio-video visits provided a valid patient-provider relationship exists [11]. Following the expiration of COVID-era federal telehealth waivers, prescribers must still conduct an appropriate clinical evaluation before issuing a new specialty prescription. For evolocumab, that evaluation typically includes a lipid panel review, cardiovascular risk assessment, and documentation of prior statin therapy.

HealthRX's NC-licensed providers can prescribe evolocumab or refer patients for compounded evolocumab through a fully remote visit. The clinical workflow mirrors in-person care: lipid panel review, ACC/AHA risk calculator scoring, documentation of statin trial, and PA submission if commercial insurance is in place. Most NC commercial plans accept PA submissions from telehealth providers using the same forms as in-person clinics [11].

Telehealth also removes a real-world barrier for patients in rural NC counties where cardiologists and lipid specialists have long wait times. A 2022 analysis in the Journal of the American Heart Association found that telehealth-initiated PCSK9 inhibitor prescribing increased appropriate prescribing rates in underserved areas by 23% compared to usual care [12].

LDL-C Targets and When Evolocumab Is Clinically Indicated

The 2018 ACC/AHA cholesterol guideline establishes an LDL-C goal of <70 mg/dL for very high-risk ASCVD patients and suggests considering a PCSK9 inhibitor when LDL-C remains at or above 70 mg/dL despite maximally tolerated statin plus ezetimibe [5]. For patients with heterozygous FH and ASCVD, the same guideline supports an LDL-C goal of <70 mg/dL [5].

FOURIER demonstrated a 59% LDL-C reduction from a median baseline of 92 mg/dL, bringing median on-treatment LDL-C to 30 mg/dL, with no statistically significant increase in adverse neurocognitive events at 26 months of follow-up [1]. A pre-specified FOURIER analysis published in Circulation found that patients who achieved LDL-C <20 mg/dL had similar safety profiles to those with higher achieved levels, supporting the concept that there is no established lower threshold below which LDL-C reduction becomes harmful [13].

The GLAGOV trial (N=968) showed that evolocumab 420 mg monthly on top of statin therapy reduced percent atheroma volume by 0.95% versus a 0.05% increase in the placebo group (P<0.001), providing direct plaque-regression evidence that goes beyond the outcomes data from FOURIER [14].

For patients with homozygous FH, the mean LDL-C reduction with evolocumab was 30% in the TESLA Part B trial (N=50), a smaller but clinically meaningful reduction in a population where LDL receptors are severely deficient [15].

Practical Cost Scenarios for North Carolina Patients in 2026

Understanding the actual monthly cost requires knowing which of four situations applies.

Scenario 1: Commercially insured, PA approved, savings card eligible. Monthly cost: $0 to $5 with the Amgen copay card. Annual savings card cap applies; cost may rise in months 11 and 12 if the $3,600 cap is exhausted.

Scenario 2: Commercially insured, PA denied or step therapy not yet completed. Monthly cost: $580 cash or whatever the pharmacy's GoodRx-negotiated rate is. Appeal using NC Session Law 2023-58 requirements and the ACC/AHA guideline language cited above [5] [8].

Scenario 3: NC Medicaid, type 2 diabetes indication. Monthly cost: standard Medicaid copay, typically $3 to $8 per fill if covered under the PDL. Requires PA documentation matching NC DHHS Clinical Coverage Policy 8C criteria [4].

Scenario 4: Uninsured or Medicaid non-diabetes patient. Options include the Amgen Repatha Assist free drug program (income-based), compounded evolocumab from a licensed NC 503A pharmacy at roughly $100 to $200 per month, or a HealthRX telehealth visit to assess the best route given individual clinical and financial circumstances.

Monitoring and Follow-Up After Starting Evolocumab in North Carolina

A lipid panel drawn 4 to 12 weeks after the first injection confirms LDL-C response, which is the standard interval recommended by the ACC/AHA [5]. Most NC labs report fasting lipid panels within 24 to 48 hours, and telehealth providers can review results and adjust therapy remotely under NC telehealth rules [11]. If LDL-C has not fallen by at least 40% from baseline, the most common explanations are poor injection technique, drug storage failure (Repatha requires refrigeration between 36°F and 77°F), or the rare phenomenon of anti-drug antibody formation, which occurred in 0.3% of FOURIER participants [1].

Annual lipid reassessment is standard practice for patients on stable evolocumab therapy, per the ACC/AHA 2018 guideline's recommendation to reassess cardiovascular risk and medication adherence at each routine visit [5]. The FDA label also specifies hepatic enzyme monitoring if clinically indicated, though evolocumab does not carry a liver toxicity warning comparable to statins [2].